Table 3.
Week | Pooled Effects | Pair Wise Treatment Comparisons | ||||||
---|---|---|---|---|---|---|---|---|
Bupropion SR (n = 73) | CM (n = 66) | Bupropion SR + Non-CM vs. Placebo + Non-CM | Placebo + CM vs. Placebo + Non-CM | Bupropion SR + CM vs. Placebo + Non-CM | Bupropion SR + CM vs. Bupropion SR + Non-CM | Bupropion SR + CM vs. Placebo + CM | Bupropion SR + Non-CM vs. Placebo + CM | |
3† | 3.7** (1.4 – 10.0) | 2.0 (0.8 – 4.9) | 2.3 (0.6 – 9.9) | 1.1 (0.2 – 6.0) | 5.9** (1.5 – 23.0) | 2.5* (0.9 – 7.3) | 5.3** (1.3 – 20.7) | 2.1 (0.5 – 8.9) |
4 | 2.5** (1.0 – 6.2) | 1.8 (0.8 – 4.2) | 1.1 (0.3 – 4.0) | 0.6 (0.1 – 2.9) | 3.3** (1.0 – 10.5) | 3.0** (1.0 – 9.1) | 5.3** (1.3 – 20.7) | 1.7 (0.4 – 7.6) |
5 | 2.6* (0.9 – 7.1) | 2.0 (0.8 – 5.2) | 1.6 (0.3 – 7.1) | 1.1 (0.2 – 6.0) | 4.1** (1.0 – 16.3) | 2.6 (0.8 – 8.5) | 3.7* (0.9 – 14.7) | 1.4 (0.3 – 6.4) |
6 (End of Treatment) | 2.0 (0.7 – 5.6) | 2.5* (0.9 – 7.1) | 0.9 (0.2 – 4.7) | 1.1 (0.2 – 6.0) | 3.6* (0.9 – 14.4) | 4.1** (1.0 – 16.3) | 3.2 (0.8 – 13.0) | 0.8 (0.1 – 4.2) |
12 (Follow-Up) | 2.6 (0.5 –13.6) | 1.0 (0.2 – 4.2) | 0.9 (0.1 – 6.7) | 0.2§ (0.6 – 3.8) | 1.8 (0.3 – 10.7) | 2.1 (0.4 – 12.0) | 10.5*§ (0.8 – 23.4) | 5.3§ (0.2–13.9) |
Calculated using Modified Median Unbiased Estimator of Odds Ratio and Bootstrapped 95% Confidence Interval (Parzen et al., 2002) due to cells with count zero
following initial two-week grace period
p < 0.05
p < 0.10